Review of P-gp Inhibition Data in Recently Approved New Drug Applications: Utility of the Proposed [I1]/IC50 and [I2]/IC50 Criteria in the P-gp Decision Tree


Corresponding Author:

Lei Zhang, PhD, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Building 51, Room 3106, White Oak, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA Email: